

1 **Distinguishing between COVID-19 and the common cold in a primary care setting**
2 **- comparison of patients with positive and negative SARS-CoV-2 PCR results.**

3

4 **Short title: Clinical detection of patients with COVID-19**

5

6 **Authors:**

7 Johannes Just, MD^{1*}, Marie-Therese Puth, M.Sc.², Felix Regenold¹, Klaus Weckbecker, MD^{1#},

8 Markus Bleckwenn, PhD^{3#}

9

10 **Affiliations:**

11 1: Institute of General Practice and Interprofessional Care

12 Witten/Herdecke University

13 Alfred-Herrhausen-Straße 50

14 58453 Witten

15

16 2: Department of Medical Biometry, Informatics and Epidemiology (IMBIE)

17 University Hospital Bonn

18 Sigmund-Freud-Str. 25,

19 53127 Bonn

20

21 3: Department of General Practice

22 Leipzig University

23 Medical Faculty

24 Ph.-Rosenthal-Str. 55

25 04103 Leipzig

26

27

28 * Corresponding author:

29 Dr. med. Johannes Just

30 Witten/Herdecke University

31 Alfred-Herrhausen-Straße 50

32 58455 Witten, Germany

33 tel.: 0049 – (0)2302 - 926743

34 johannes.just@uni-wh.de

35

36 # joined last authorship

37

38

39

40

41

42

43

44

45

46

47

48

49

50 **Abstract:**

51 **Background:** Combating the COVID-19 pandemic is a major challenge for health
52 systems, citizens and policy makers worldwide. Early detection of affected patients
53 within the large and heterogeneous group of patients with common cold symptoms is an
54 important element of this effort, but often hindered by limited testing resources and the
55 lack of pathognomonic symptoms in COVID-19. Therefore, we aimed to identify
56 predictive risk factors for a positive SARS-CoV-2 PCR (CovPCR) result in a primary
57 care setting.

58 **Method:** We performed a multi-center cross-sectional cohort study on predictive clinical
59 characteristics for a positive CovPCR over a period of 4 weeks in primary care patients
60 in Germany.

61 **Findings:** In total, 374 patients in 14 primary care centers received CovPCR and were
62 included in this analysis. The median age was 44.0 (IQR: 31.0-59.0) and a fraction of
63 10.7% (n=40) tested positive for COVID-19. Patients who reported anosmia had a
64 higher odds ratio (OR: 4.54; 95%-CI: 1.51-13.67) for a positive test result while patients
65 with a sore throat had a lower OR (OR: 0.33; 95%-CI: 0.11-0.97). Patients who had a
66 first grade contact with an infected persons and showed symptoms themselves also had
67 an increased OR for positive testing (OR: 5.16; 95% CI: 1.72-15.51). This correlation
68 was also present when they themselves were still asymptomatic (OR: 12.55; 95% CI:
69 3.97-39.67).

70 **Conclusions:** Several anamnestic criteria may be helpful to assess pre-test probability
71 of COVID-19 in patients with common cold symptoms

72 **Keywords:** COVID-19; PCR; positive-predictive value, risk factors

73

74

75 **Background**

76 The COVID-19 pandemic is a major challenge for health systems, citizens and policy
77 makers worldwide [1]. The early political implementation of individual distancing has
78 slowed down the reproduction rate of the virus in Germany significantly [2]. In addition,
79 compared to other countries, Germany has implemented an intensive testing strategy
80 for new infections using PCR swab testing, funded by the national social health
81 insurance system (statutory health insurance). According to data from “Robert-Koch
82 Institut” (RKI), roughly an equivalent to the CDC in the US, 176 participating laboratories
83 reported a number of 348,619 PCR tests carried out in calendar week 12/2020 (419
84 tests/100.000 inhabitants). The tests were mostly carried out in doctors' (GP's)
85 practices, newly formed COVID-19 test centers and hospitals [3].

86

87 In view of the potentially exponential increase in the number of new cases and finite
88 laboratory resources (test stations, reagents, etc.), there is an urgent need to collect
89 and evaluate clinical data on the clinical features of tested patients. Of particular interest
90 is the question of how far positive and negative patients differ in their initial clinical
91 presentation. The more precisely physicians use SARS-CoV-2 PCR (CovPCR) testing,
92 the more efficient it is. Statistically, this is reflected in Baye's theorem: The quality of a
93 test is not only determined by specificity and sensitivity, but also depends on the pre-

94 test probability of the event to be tested. Thus, if the pre-test probability for COVID-19 is
95 higher, the probability that a CovPCR-positive patient is actually ill (positive-predictive
96 value = PPV) is increased [4].

97
98 In this paper we aimed to identify predictive risk profiles for a positive CovPCR result in
99 primary care.

100

101 **Method**

102 Study design

103 In this multi-center, cross-sectional study, the characteristics of patients who tested
104 positive and negative for COVID-19 were assessed. A total of 26 office-based
105 specialists for internal and/or general medicine with a full primary care mandate from 14
106 different locations participated in the study.

107

108 Setting

109 All locations collected patient-related data based on a uniform quality standard in the
110 documentation of COVID-19 suspect cases that we provided. Each site reported
111 anonymous data on all CovPCR swabs taken. All data were noted on a paper-based,
112 structured documentation form and passed on anonymously for evaluation. The
113 documentation form was prepared on the basis of the recommendations of the RKI as
114 well as the available evidence on symptoms and risk factors for COVID-19 and was
115 subjected to pre-testing with experienced family physicians [5-8]. The test reason
116 "Patient is contact person without symptoms" was included in addition to the test

117 reasons recommended by the RKI, as it had already been used frequently in everyday
118 practice. The study period was from 24.03.2020 to 17.04.2020 - this period was chosen
119 because the RKI criteria for carrying out a CovPCR remained unchanged.

120

121 Participants

122 The participating GP's practices represented a "convenience sample". Selection criteria
123 were the performance of smear tests, structured documentation and willingness to
124 participate. All patients who received CovPCR in the participating GP's practices within
125 the study period were eligible for inclusion. Patients whose tests had been carried out
126 for procedural reasons and did not correspond to a specific clinical indication were
127 excluded (e.g. testing of recovered patients after end of quarantine). There were no
128 other exclusion criteria.

129

130 Variables and data sources

131 The variables under study included: Age, sex, reason for the test, risk factors,
132 symptoms leading to the test, result expected by the GP and actual CovPCR results. All
133 information was extracted from the anonymized documentation forms

134

135 Bias

136 In order to ensure that there was no excessive distortion in the patient collective due to
137 the convenience sampling of practices, age and sex of the tested persons were
138 compared with demographic data from a large national sample of CovPCR-tests [3].

139

140 Statistical methods

141 Data entry was performed twice and the data sets were compared digitally, any
142 deviations were checked and a plausibility check of the data entered was performed.

143 The statistical evaluation was carried out with the statistics program R. In addition to the
144 descriptive statistics, initial chi-square tests were performed for different potential
145 influencing factors (symptoms, test reason, etc.) on the test result (CovPCR positive
146 yes/no). Statistically significant influencing factors were then transferred to a logistic
147 regression model to check their effect strength. Missing data were reported in the
148 descriptive part, for the regression model missing values were assigned to the more
149 frequent result (deviation to the middle), a proportion of missing values >5% was not
150 exceeded per variable.

151 The study design was reviewed by the ethics committee of the University of Leipzig,
152 Germany under the procedure number 184/20-ek, there were no ethical concerns.

153 This study was conducted without external financial support.

154

155 **Results**

156 The participating practices tested n=374 patients per CovPCR in the investigated
157 period. Of these, 10.7% (n=40) tested positive. The symptom anosmia, as well as
158 contact with infected persons, was associated with a positive CovPCR result.

159


160 A total of 26 specialists with a general practitioner mandate at 14 different locations
161 (individual and group practices) from North Rhine-Westphalia, Rhineland-Palatinate,
162 Hesse and Saxony-Anhalt (four of 16 federal German states) took part in the study. All

163 practices are located in urban and rural districts with moderate to increased COVID-19
164 activity (cumulative incidence 50-250 cases per 100,000 inhabitants) [2].

165 Parallel to the number of new infections reported throughout Germany, the number of
166 tests performed decreased in the course of the study, as did the rate of positively tested
167 patients.

168

169 Figure 1: Number of tests separated by test reason per calendar week



170

171 Of the examined patients, 58.5% were female and the median age was 44 years.

172 Further characteristics of the investigated cohort can be found in table 1.

173

174 Table 1: Patient characteristics

	Total (n = 374)	COVID-19 negative (n = 334)	COVID-19 positive (n = 40)	p-value
Age				0.147*
MV (SD)	47.0 (20.2)	46.4 (19.7)	52.4 (23.5)	
median (Q1-Q3)	44.0 (31.0- 59.0)	43.5 (31.0- 58.0)	52.0 (31.2- 73.2)	
missing, n (%)	4 (1.1)	4 (1.2)	0 (0.0)	
gender, n (%)				0.475
male	154 (41.2)	140 (41.9)	14 (35.0)	
female	217 (58.0)	191 (57.2)	26 (65.0)	
missing	3 (0.8)	3 (0.9)	0 (0.0)	
reason for testing, n (%)				<0.001
First grade contact (has symptoms)	72 (19.3)	58 (17.4)	14 (35.0)	
First grade contact	40 (10.7)	27 (8.1)	13 (32.5)	

(has no symptoms)				
Indication of viral pneumonia	13 (3.5)	12 (3.6)	1 (2.5)	
Works in medical profession	51 (13.6)	47 (14.1)	4 (10.0)	
belongs to risk group	60 (16.0)	59 (17.7)	1 (2.5)	
free capacity/other	134 (35.8)	127 (38.0)	7 (17.5)	
missing	4 (1.1)	4 (12.0)	0 (0.0)	
GP expects positive result, n (%)				<i>0.010</i>
no	245 (65.5)	227 (68.0)	18 (45.0)	
yes	119 (31.8)	99 (29.6)	20 (50.0)	
missing	10 (2.7)	8 (2.4)	2 (5.0)	
Number of risk factors, n (%)				N/A
none	187 (50.0)	168 (50.3)	19 (47.5)	
one or two	138 (36.9)	125 (37.4)	13 (32.5)	

more than two	49 (13.1)	41 (12.3)	8 (20.0)	
---------------	-----------	-----------	----------	--

175 *Mann-Whitney U Test

176 MV=mean value; SD=Standard deviation; Q1 = 25%-quantile; Q3 = 75%-quantile

177

178

179 The most frequent symptoms at the presentation of patients who later tested positive for
 180 COVID-19 were cough, fever, anosmia and muscle pain. The most common symptoms
 181 at presentation of patients who later tested negative for COVID-19 were cough, sore
 182 throat, fatigue and fever. A complete list of symptoms is displayed in table 2.

183

184 Table 2: Symptoms of patients tested negative and positive for COVID-19

Variable	COVID-19 negative (n = 307)		COVID-19 positive (n = 27)		p-value
	n	%	n	%	
cough (n, %)	214	69.7	19	70.4	1.000
Sore throat (n, %)	120	39.1	5	18.5	0.038
fatigue (n, %)	89	29.0	5	18.5	0.371
fever (n, %)	84	27.4	9	33.3	0.507
nasal congestion (n, %)	84	27.4	5	18.5	0.373
muscle pain (n, %)	59	19.2	7	25.9	0.448

dyspnea (n, %)	56	18.2	4	14.8	0.798
headache (n, %)	47	15.3	3	11.1	0.780
anorexia (n, %)	28	9.1	2	7.4	1.000
diarrhea (n, %)	23	7.5	1	3.7	0.707
anosmia (n, %)	22	7.2	7	25.9	0.005
chills (n, %)	20	6.5	5	18.5	0.040
nausea (n, %)	11	3.6	0	0.0	1.000
vomiting (n, %)	4	1.3	0	0.0	1.000
other symptoms (n, %)	37	12.1	3	11.1	1.000

185 Asymptomatic patients (n=40) were excluded in this table.

186

187 The regression model used to determine the individual effect sizes included all patient
 188 characteristics that showed a statistically significant influence on the test result in the
 189 Chi-square test. The odds ratio (OR) for a positive CovPCR was increased in patients
 190 who had contact with an infected person who were older and in patients with anosmia
 191 and decreased in patients suffering from a sore throat. Table 3 shows all results of the
 192 regression model.

193

194 Table 3: Logistic regression model: factors influencing positive CovPCR

Variable	COVID-19 negative (n=330) n (%)	COVID-19 positive (n=40) n (%)	adjusted OR (95% CI)	p-value
First grade contact (has symptoms)	58 (17.5)	14 (35.0)	5.16 (1.72-15.51)	0.002
First grade contact (has no symptoms)	27 (11.2)	13 (32.5)	12.55 (3.97-39.67)	<0.001
Free capacity/other	125 (37.9)	7 (17.5)	1.50 (0.46-4.87)	0,497
age*	46,4 (19.7)	52,4 (23.5)	1.02 (1.00-1.04)	0,019
GP expects positive result	97 (29.4)	20 (50.0)	1.98 (0.90-4.38)	0.092
chills	20 (6.1)	5 (12.5)	2.80 (0.83-9.43)	0.117
Anosmia	22 (6.7)	7 (17.5)	4.54 (1.51-13.67)	0.011

sore throat	118 (35.8)	5 (12.5)	0.33 (0.11-0.97)	0.029
-------------	------------	----------	---------------------	-------

195 OR = odds ratio; CI = confidence intervals

196 * mean value (standard deviation); Nagelkerke R² 0.265

197

198

199 Discussion

200

201 Main result

202 The main result of this work is the shown correlation between a positive CovPCR and
203 the symptom anosmia as well as a confirmed contact with an infected person,
204 regardless of whether the tested person itself had symptoms or not.

205

206 Strengths and limitations

207 In this work, predictive factors for a positive CovPCR were investigated for the first time.
208 The evaluation was performed with a multicentric approach and was based on a
209 common documentation standard. The selection of the practices was non-randomized,
210 as a rapid implementation of the study was preferred to a lengthier randomized
211 selection in respect to the pandemics' rapid evolution. This may have resulted in a
212 distortion of the investigated patient collective, although, no conspicuous deviations
213 were found in comparison to the demographic data of all patients tested in Germany as
214 published by the RKI: the age median in our population was 44 years (IQR: 31-59)

215 compared to 42 years (IQR: 29-56) in a sample of +1.000.000 patients tested in
216 Germany [3]. Therefore, the results could be considered representative for patients in
217 Germany. The major limitation of this study is the small sample size resulting in wide
218 CIs and a connected uncertainty regarding the strength and direction of several effects.
219 Still, this is the first study to show clinical risk factors for a positive CovPCR and its
220 results are in line with the current evidence base [5-8].

221

222 **Number of patients tested and rates of positives**

223 The proportion of test-positive patients in our population was 10.7%, which is slightly
224 above the average of positive tests performed in Germany during this period (North
225 Rhine-Westphalia (9.3%), Rhineland-Palatinate (9.6%), Hesse (11.8%)) [3]. The
226 number of tests decreased towards the end of the investigation period, which parallels
227 the decreasing number of new COVID-19 infections in Germany as well as the end of
228 the pandemic cold season in early spring.

229

230 **Factors that were associated with a negative test result**

231 Negative tests were associated with the symptom "sore throat". This result is consistent
232 with the low prevalence of the symptom "sore throat" in confirmed COVID-19 cases [6].
233 The correlation found between age and test results is marginal (younger people were
234 tested negative more often) and may be explained by local outbreaks in nursing homes.
235 This effect will most likely disappear due to diffusion processes during the course of the
236 pandemic and may not be present in countries with a more homogenous spreading
237 pattern.

238

239 **Factors that were associated with a positive test result**

240 Positive tests were associated with confirmed contact. This was to be expected, but it
241 was surprising that this also applied to asymptomatic patients. He et al. concluded that
242 45% of infections occur in the pre-symptomatic phase of the patient, i.e. the patient is
243 still asymptomatic but already has large amounts of virus replicated in the throat and is
244 highly contagious [9]. This result underlines the particular relevance of contact
245 anamnesis for the test decision, but also the relevance of early isolation of potentially
246 affected contacts.

247 Of particular clinical importance is the observed association between the symptom
248 anosmia and a positive PCR result. Anosmia has already been described as a relevant
249 COVID-19 symptom in other studies, but this is the first study to show that anosmia may
250 be a useful discriminator between COVID-19 and other, endemic respiratory tract
251 infections [8,10,11]. Since the examined patients mainly presented with fever, cough,
252 muscle pain and other cold symptoms, which are common with endemic respiratory
253 tract infections, anosmia can be an important indication of COVID-19. Although anosmia
254 is a secondary symptom of a variety of viral respiratory infections, the incidence of
255 anosmia without acute or chronic rhinitis in COVID-19 is striking [8,10-12]. Reporting
256 from our clinical experience with COVID-19, anosmia was sometimes so pronounced in
257 COVID-19 patients that it was presented as the sole symptom upon presentation.
258 Therefore, we recommend that patients are always asked for fever, cough, dyspnea and
259 anosmia as part of the initial stratification process. In case of isolated anosmia in the
260 absence of chronic or acute rhinosinusitis, we recommend a testing for COVID-19

261 infection, as already suggested in a French case series by Villalba et al. and others
262 [8,11,13]

263

264 **Conclusion**

265 Rapid testing of first degree contacts, consistent tracing of infection chains and
266 quarantine will remain essential parts of the COVID-19 containment strategy. Our data
267 show that the testing of all first-degree contacts, including asymptomatic ones can be of
268 merit and that anosmia, even as an isolated symptom is a clear indication of COVID-19
269 infection.

270

271 **List of abbreviations**

272 CovPCR: SARS-CoV-2 PCR

273 PPV: positive-predictive value

274

275 **Declarations**

276 Ethics approval and consent to participate:

277 The study design was reviewed by the ethics committee of the University of Leipzig,
278 Germany under the procedure number 184/20-ek, there were no ethical concerns.

279 Consent to participate was not applicable according to national regulations as routine
280 treatment data was anonymously passed on to researchers. The ethics committee
281 stated no concerns regarding the method of data collection including consent to
282 participate.

283

284 Consent for publication:

285 All authors gave their consent for publication

286

287 Availability of data and materials:

288 The datasets generated and analysed during the current study are available from the
289 corresponding author on reasonable request.

290

291 Competing interests:

292 Conflict of interest: JJ, MP, KW and MB declare no conflict of interest. Felix Regenold
293 holds shares <5% of a regulatory affairs service company (Dr. Regenold GmbH) which
294 is run by a family member.

295

296 Funding:

297 There was no external funding for this study.

298

299 Authors contributions:

300 JJ, KW and MB designed the study, supervised data collection and drafted main parts
301 of the paper. FR gathered data, performed statistical analysis and contributed to the
302 development of the paper. MP performed statistical analysis and helped drafting the
303 paper. All authors read and approved the final manuscript.

304

305 Acknowledgements:

306 We thank all participating practices for their effort.

307

308 **References**

- 309 1. Statement on the second meeting of the International Health Regulations (2005)
310 Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV) [Internet].
311 [cited 2020 Apr 1]. Available from: [https://www.who.int/news-room/detail/30-01-2020-](https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov))
312 [statement-on-the-second-meeting-of-the-international-health-regulations-\(2005\)-](https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov))
313 [emergency-committee-regarding-the-outbreak-of-novel-coronavirus-\(2019-ncov\)](https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov))
- 314 2. RKI: Daily situation report on COVID-19. Available from:
315 [https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/2020-](https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/2020-04-19-de.pdf?__blob=publicationFile)
316 [04-19-de.pdf?__blob=publicationFile](https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/2020-04-19-de.pdf?__blob=publicationFile)
- 317 3. RKI: epidemiological update 15/2020. SARS-CoV-2-testing numbers. [cited 2020 Apr 15].
318 Available from:
319 [https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2020/Ausgaben/15_20.pdf?__blob=pu](https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2020/Ausgaben/15_20.pdf?__blob=publicationFile)
320 [blicationFile](https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2020/Ausgaben/15_20.pdf?__blob=publicationFile)
- 321 4. Schneider A, Dinant G-J, Szecsenyi J. Stepwise diagnostic workup in general practice as a
322 consequence of the Bayesian reasoning. *Z Arztl Fortbild Qualitatssich.* 2006;100(2):121–7.
- 323 5. RKI: Testing guidelines for doctors [Internet]. [cited 2020 Apr 1]. Available from:
324 [https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Massnahmen_Verdachtsfal](https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Massnahmen_Verdachtsfall_Infografik_DINA3.pdf?__blob=publicationFile)
325 [l_Infografik_DINA3.pdf?__blob=publicationFile](https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Massnahmen_Verdachtsfall_Infografik_DINA3.pdf?__blob=publicationFile)
- 326 6. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected
327 with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020 Feb 15;395(10223):497–506.
- 328 7. Lechien JR, Chiesa-Estomba CM, De Siaty DR, Horoi M, Le Bon SD, Rodriguez A, et al.
329 Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of
330 the coronavirus disease (COVID-19): a multicenter European study. *Eur Arch*
331 *Otorhinolaryngol* [Internet]. 2020 Apr 6; Available from: <http://dx.doi.org/10.1007/s00405->

332 020-05965-1

333 8. Spinato G, Fabbris C, Polesel J, Cazzador D, Borsetto D, Hopkins C, et al. Alterations in
334 Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection. JAMA
335 [Internet]. 2020 Apr 22; Available from: <http://dx.doi.org/10.1001/jama.2020.6771>

336 9. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding
337 and transmissibility of COVID-19. Nat Med [Internet]. 2020 Apr 15; Available from:
338 <http://dx.doi.org/10.1038/s41591-020-0869-5>

339 10. Brann DH, Tsukahara T, Weinreb C, Lipovsek M, Van den Berge K, Gong B, et al. Non-
340 neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests
341 mechanisms underlying COVID-19-associated anosmia [Internet]. Available from:
342 <http://dx.doi.org/10.1101/2020.03.25.009084>

343 11. Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, et al. Self-reported
344 Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2
345 Infection: A Cross-sectional Study [Internet]. Clinical Infectious Diseases. 2020. Available
346 from: <http://dx.doi.org/10.1093/cid/ciaa330>

347 12. van Riel D, Verdijk R, Kuiken T. The olfactory nerve: a shortcut for influenza and other viral
348 diseases into the central nervous system [Internet]. Vol. 235, The Journal of Pathology.
349 2015. p. 277–87. Available from: <http://dx.doi.org/10.1002/path.4461>

350 13. Villalba NL, Maouche Y, Ortiz MBA, Sosa ZC, Chahbazian JB, Syrovatkova A, et al.
351 Anosmia and Dysgeusia in the Absence of Other Respiratory Diseases: Should COVID-19
352 Infection Be Considered? Eur J Case Rep Intern Med. 2020 Apr 3;7(4):001641.